ArticleBMC cancer2025

Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.

Pei-Chang Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.